News and Articles

With a zest and appreciation for life, at 77 years old, Barbara considered herself the picture of perfect health. But that changed in June of 2025 when she was diagnosed with metastatic HR-/HER2+ breast cancer.

Partnership brings new cancer trial and treatments to patients in New York City and Westchester.

We’re among the first centers in the country to treat patients in the new “pre-chemo” setting. Here’s what we’re learning—and what we’re still working to understand.

Enrollment for this year’s FutureSolve program is nearly double last year’s.

RadioNexus is the world’s first radiopharmaceutical-focused clinical trials network.

Prostate cancer patients whose cancer has spread have a game-changing new option for treatment.

BAMF Health dosed the first patient in the U.S. for Radiopharm Theranostics’ Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis.

This non-invasive clinical trial aimed to understand the prevalence of a specific biomarker in HR-/HER2+ breast cancer.

BAMF Health Chief Medical Advisor Dr. Harshad Kulkarni shares his expert perspectives on the field of Theranostics and where it’s headed.

Mike credits the radiopharmaceutical therapy he received at BAMF for shrinking his neuroendocrine tumor and saving his life.

After a decades-long battle with neuroendocrine cancer, Nolan hopes treatment at BAMF Health will stop his cancer in its tracks.

Dr. Abass Alavi, a pioneering figure in the field of molecular imaging and nuclear medicine, and his wife Jane Alavi, made a $100,000 donation to our Foundation.